Mid- and Late-Life Diabetes in Relation to the Risk of Dementia
A Population-Based Twin Study

Weili Xu,1 Chengxuan Qiu,1 Margaret Gatz,2,3 Nancy L. Pedersen,2,3 Boo Johansson,4 and Laura Fratiglioni1

OBJECTIVE—We aimed to verify the association between diabetes and the risk of dementia, Alzheimer’s disease, and vascular dementia in twins and to explore whether genetic and early-life environmental factors could contribute to this association.

RESEARCH DESIGN AND METHODS—This study included 13,693 twin individuals aged ≥65 years. Dementia was diagnosed according to DSM-IV (Diagnostic Manual of Mental Disorders, 4th ed.) criteria. Information on diabetes was collected from the inpatient registry and self- or informant-reported history of diabetes. Data were analyzed following two strategies: 1) unmatched case-control analysis for all participants using generalized estimating equation (GEE) models and 2) cotwin matched case-control analysis for dementia-discordant twin pairs using conditional logistic regression.

RESULTS—Of all participants, 467 were diagnosed with dementia, including 292 with Alzheimer’s disease and 175 with vascular dementia, and an additional 170 were diagnosed with questionable dementia. Diabetes was present in 1,396 subjects. In GEE models, diabetes was associated with adjusted odds ratios (ORs) (95% CI) of 1.89 (1.51–2.38) for dementia, 1.69 (1.61–2.36) for Alzheimer’s disease, and 2.17 (1.36–3.47) for vascular dementia. Compared with late-life diabetes (onset age ≥65 years), the risk effect of mid-life diabetes (onset age <65 years) on dementia was stronger. Conditional logistic analysis of 210 dementia-discordant twin pairs led to ORs of 2.41 (1.05–5.51) and 0.68 (0.30–1.53) for dementia related to mid- and late-life diabetes, respectively.

CONCLUSIONS—Diabetes increases the risk of Alzheimer disease and vascular dementia. The risk is stronger when diabetes occurs at mid-life than in late life. Genetic and early-life environmental factors might contribute to the late-life diabetes–dementia association but could not account for the mid-life diabetes–dementia association. Diabetes 58:71–77, 2009

From the 1Department of Neurobiology, Care Sciences and Society, Aging Research Center, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; the 2Department of Psychology, University of Southern California, Los Angeles, California; the 3Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; and the 4Department of Psychology, University of Gothenburg, Gothenburg, Sweden.

Corresponding author: Weili Xu, weili.xu@ki.se.

Received 30 April 2008 and accepted 8 October 2008.

Published ahead of print at http://diabetes.diabetesjournals.org on 24 October 2008. DOI: 10.2337/db08-0586.

© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

RESEARCH DESIGN AND METHODS

Population-based longitudinal studies (1–12) have shown that the risk of dementia in general is increased in people with diabetes. Even prediabetes has been associated with an increased risk of dementia and Alzheimer disease (13). Although diabetes may be linked to dementia through several biologically plausible pathways (14), our understanding of the mechanisms for such an association is still limited. Both dementia and diabetes are complex age- and lifestyle-related disorders. In addition to strong influence of environmental elements, genetic components also play a part in both Alzheimer’s disease and diabetes (15,16). Epidemiological and clinical studies (11,17–19) have reported that environmental factors acting in early life, such as birth weight and childhood socioeconomic situation, are also involved in the development of diabetes as well as dementia. Evidence from genetic and epidemiological studies (20,21) has indicated that genetic and environmental factors may interact to affect the association between diabetes and dementia during the life course.

The recent upsurge of interest in applying a life-course approach to chronic disease epidemiology and the hypothesis of “developmental origins of adult disease” prompt renewed attention to twin studies. Twins provide naturally matched pairs, in which confounding effects of a large number of potentially causal factors (e.g., genetics and childhood environment) may be removed when comparisons are made between twins. Because twins are generally reared together, they share their early-life environment. Twin studies involving a life-course approach may help to identify genetic influences and timing of environmental influences on the relationship between age-related disorders. In the current study, we sought to 1) verify the association between diabetes and risk of dementia and its main subtypes in twins, 2) examine whether the effect of diabetes on dementia risk varies according to age of diabetes onset, and 3) explore whether genetic and early-life familial environmental factors could explain this association using data from the population-based Swedish twin cohort.
The HARMONY Study population

**Screening phase (1998-2001)**

- **20,206** Eligible twins aged ≥65
- **14,435** (71.4%) Reached by telephone
- **5,771** Dropouts
- **712** Not interviewable

**Clinical phase (1998-2002)**

- **1,357** Clinical diagnosis available
- **467** Dementia
- **170** Questionable
- **1,056** non-demented

- **13,723** Participated in screening tests
- **13,693** Participants with complete cognitive test data
- **30** Missing cognitive test data

**1,939** Invited to the clinical phase

**1,365** Twin individuals
- **13,665** Conventional case-control
- **13,693** Matched case-control

**Multinomial Logistic Regression**
- **637** Dementia+Questionable Controls
- **210** Dementia discordant pairs

**Strategy I**

**Strategy II**

- **13,693** Twin individuals
- **13,693** Controls
- **13,665** Both demented
- **4,274** Both non-demented
- **5,117** Single twins

FIG. 2. Two analytical strategies for the HARMONY study.

Covariates and identification of diabetes. For 13,693 individuals who participated in the screening phase, information concerning demographic factors, education, health status and behavior, common diseases, use of medications, height, and weight was obtained during the telephone interview. For twins who had completed surveys by the Swedish Twin Registry in 1961, 1963, and 1967 for the older cohort and in 1973 for the younger cohort, information on height and weight is available. Information on history of vascular disorders (hypertension, heart disease, and stroke) was derived from the inpatient registry system. Each record in the system included up to eight discharge diagnoses according to the ICD-7 through 1968. ICD-8 was used by the register system until 1986; since 1987 the ICD-9 has been used. Medical conditions derived from the inpatient registry database included hypertension (ICD-7 codes 444–447, ICD-8 codes 400–404, and ICD-9 codes 401–405), ischemic heart disease (ICD-7 codes 420–421, ICD-8 and -9 codes 410–414), cardiac dysrhythmia, heart failure or other myocardial insufficiency (ICD-7 codes 433 and 434, ICD-8 and -9 codes 427 and 428), and stroke (ICD-7 codes 330–334, ICD-8 and -9 codes 430–435). Vascular diseases including hyperton- 

FIG. 1. Flowchart of the study population in the HARMONY study.

individuals were invited to the clinical phase, including participants who were screened as positive for cognitive dysfunction, subjects who were with suspected dementia, or demented twin’s partner and normal control subjects. Clinical diagnoses were available for 1,357 individuals. The participation rates were 71.4% for the screening phase and 70.0% for the clinical phase (Fig. 1).

Informed consent was required from all participants during the telephone interview and again in the clinical phase. The data collection procedures were reviewed and approved by the Swedish Data Inspection Board, Stockholm, Sweden, the Regional Ethics Committee at Karolinska Institutet, Stockholm, and the institutional review board of the University of Southern California.

**Diagnosis of dementia and its major subtypes.** A two-step procedure was used in the diagnosis of dementia. The first step was cognitive screening through a telephone interview using the validated TELE questionnaire for the twins (24,25) and the Blessed Dementia Rating Scale for the informants (26). The TELE and Blessed Dementia Rating Scale were combined into an ordinal scale with scores ranging from 0 (cognitive intact) to 5 (cognitive dysfunction) (24). The second step was a full clinical workup that entailed a visit by an assessment team composed of a nurse and a physician. The assessment team made an initial diagnosis based on a protocol that followed the Consortium to Establish a Registry for Alzheimer’s Disease and included physical and neurological examination, a review of medical history, informant interview, and a neuropsychological assessment. The neuropsychological battery included the Mini-Mental State Examination; the Consortium to Establish a Registry for Alzheimer’s Disease word list immediate and delayed recall, verbal fluency, block design, figure copying, judgment, information, symbol-digit, and prospective memory; as well as the Memory in Reality test. These preliminary diagnoses were reviewed by a diagnostic board consisting of a neurologist and a neuropsychologist. Clinical diagnoses of dementia followed DSM-IV criteria (27). The case subjects completely fulfilling the DSM-IV criteria were diagnosed as having “dementia,” in contrast with a category of “questionable dementia,” which was used for individuals who did not fulfill one of the first three DSM-IV diagnostic criteria but did exhibit either cognitive impairment or functional disability. Participants were first classified as demented, questionable, or non-demented and then given a differential diagnostic for dementia subtype for demented subjects (23). Differential diagnoses were made according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association criteria for Alzheimer’s disease (28) and the National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l’Enseignement en Neurosciences criteria for vascular dementia (29).

More details of the clinical examination and diagnostic procedure have been reported previously (24). The age of dementia onset was estimated by the assessment team based on information that was obtained from a detailed informant interview. Age at onset was defined as the age when definite and enduring symptoms of dementia first appeared (30).
pals are analyzed, genetic confounding can be suspected. In contrast, if a significant association remains when using cotwin matched pairs, the influences of genetic or early environmental factors on the association are likely to be marginal (22). We hypothesized that diabetes would be a significant risk factor for dementia in a classical case-control analysis, whereas in the matched-pair analysis, by controlling for genetic, maternal (maternal nutrition status and disease) (17,18), and environmental factors shared by twins, we would find an attenuated association between diabetes and dementia. Logistic regression was used to test the difference in ORs from the GEE model and conditional logistic regression by examining the difference of diabetes among unmatched versus cotwin control subjects (23).

Age, sex, education, zygotic status, vascular factors (i.e., heart disease including ischemic heart disease, cardiac dysrhythmia and heart failure, stroke, and hypertension), and BMI were considered as potential confounders in all models. Education was missing in 155 subjects. The expectation maximization imputation method was used to replace the missing information based on Little’s test for missing completely at random. The statistical analyses were performed using SAS statistical software version 9.1 (SAS institute, Cary, NC) and SPSS 15.0 (SPSS, Chicago, IL).

RESULTS
Among 13,693 participants, 467 (3.4%) received a diagnosis of dementia including 292 with Alzheimer’s disease and 105 with vascular dementia, and an additional 170 (1.4%) were diagnosed with questionable dementia. The prevalence of dementia was 3.9% in female and 2.7% in male (χ² = 17.5, P < 0.001). The prevalence of dementia in this Swedish twin cohort was comparable with several major epidemiological studies of dementia prevalence in Europe and the U.S. (23). The estimated mean age of dementia onset was 76.8 years.

Of 13,693 participants, 1,288 were self-reported and 99 were informant-reported as having diabetes in the inpatient registry. In total, diabetes was identified in 1,424 subjects (10.4%), including 28 type 1 diabetic patients (1.9% of all diabetic patients). The prevalence of type 2 diabetes (1,396) was 9.8% in female and 11.2% in male subjects (χ² = 6.83, P = 0.009). The mean age of type 2 diabetes onset was 63.8 years.

Table 1 shows the characteristics of the study participants by dementia status. Compared with nondemented participants, subjects with dementia or questionable dementia were older, had a lower level of education and BMI at the time of assessment (using categorical variable as covariate in following analyses), had a higher proportion of monogygotic and same-sex dizygotic zygosity, and were more likely to have type 2 diabetes, stroke, and heart disease. Data on current BMI were missing in 1,614 twins. The prevalence of dementia and questionable dementia was 4.7% in participants with BMI available and 4.4% in participants with missing BMI (χ² = 0.26, P = 0.601). In the subsequent analyses, 28 patients with type 1 diabetes were excluded.

Characteristics of the 1,396 patients with type 2 diabetes are reported in Table 2. Compared with people with late-onset diabetes, participants with mid-life diabetes had

| Characteristics of the study participants (n = 13,693) by dementia diagnosis |
|----------------------------------|--------------------|----------------|
| No dementia                      | Questionable dementia | Dementia       |
| n                                | 13,056             | 170            | 467            |
| Age (years)                      | 73.1 ± 6.4         | 79.8 ± 6.8     | 81.5 ± 6.6     | <0.001 |
| Female sex                       | 7,281 (55.8)       | 84 (49.4)      | 302 (64.5)     | <0.001 |
| Education (years)*               | 8.6 ± 3.0          | 7.9 ± 2.8      | 7.4 ± 2.4      | <0.001 |

| Zygotic status                  |
|----------------------------------|
| Monozygotic                     | 3,070 (23.5)       |
| Same sex dizygotic              | 5,404 (41.4)       |
| Opposite sex dizygotic          | 4,351 (33.3)       |
| Indeterminate                   | 231 (1.8)          |

| Type 2 diabetes                 | 1,257 (9.6)        |
| Type 1 diabetes                 | 28 (0.2)           |
| Stroke                           | 907 (7.2)          |
| Heart disease                    | 1,540 (11.8)       |
| Hypertension                     | 4,334 (33.2)       |
| BMI (kg/m²)                      | 25.1 ± 3.7         |
| <25                              | 6,024 (46.1)       |
| 25–29.99                        | 4,531 (34.7)       |
| ≥30                             | 958 (7.3)          |
| Missing                          | 1,543 (11.8)       |

Data are n (%) or means ± SD. *A total of 155 subjects had missing value of education.

RESULTS
Among 13,693 participants, 467 (3.4%) received a diagnosis of dementia including 292 with Alzheimer’s disease and 105 with vascular dementia, and an additional 170 (1.4%) were diagnosed with questionable dementia. The prevalence of dementia was 3.9% in female and 2.7% in male subjects (χ² = 17.5, P < 0.001). The prevalence of dementia in this Swedish twin cohort was comparable with several major epidemiological studies of dementia prevalence in Europe and the U.S. (23). The estimated mean age of dementia onset was 76.8 years.

Of 13,693 participants, 1,288 were self-reported and 99 were informant-reported as having diabetes at the screening phase, which covered 276 (88.2%) of 313 subjects recorded as having diabetes in the inpatient registry. In total, diabetes was identified in 1,424 subjects (10.4%), including 28 type 1 diabetic patients (1.9% of all diabetic patients). The prevalence of type 2 diabetes (1,396) was 9.8% in female and 11.2% in male subjects (χ² = 6.83, P = 0.009). The mean age of type 2 diabetes onset was 63.8 years.

Table 1 shows the characteristics of the study participants by dementia status. Compared with nondemented participants, subjects with dementia or questionable dementia were older, had a lower level of education and BMI at the time of assessment (using categorical variable as covariate in following analyses), had a higher proportion of monogygotic and same-sex dizygotic zygosity, and were more likely to have type 2 diabetes, stroke, and heart disease. Data on current BMI were missing in 1,614 twins. The prevalence of dementia and questionable dementia was 4.7% in participants with BMI available and 4.4% in participants with missing BMI (χ² = 0.26, P = 0.601). In the subsequent analyses, 28 patients with type 1 diabetes were excluded.

Characteristics of the 1,396 patients with type 2 diabetes are reported in Table 2. Compared with people with late-onset diabetes, participants with mid-life diabetes had

| Table 2 |
|---------|
| Clinical characteristics of patients with type 2 diabetes by onset age of diabetes (n = 1,396) |
|---------|
| n       |
| All patients |
| <65 years |
| ≥65 years |
| P       |
| Age (years) | 74.4 ± 6.6 | 71.5 ± 5.4 | 77.0 ± 6.5 | 0.001 |
| Female    | 751 (52.6) | 307 (41.9) | 426 (58.1) | 0.001 |
| Onset age | 64.2 ± 12.2 | 54.6 ± 10.2 | 72.4 ± 6.2 | <0.001 |
| Duration (years) | 8.0 | 14.0 | 3.0 | <0.001 |

Data are n (%) or means ± SD, unless otherwise indicated.
longer duration of diabetes and higher proportion of treatment with insulin. In the multinomial logistic analysis including the whole study population, diabetes was significantly associated with an increased risk of both dementia and questionable dementia. As the diabetes-related ORs were similar for dementia and questionable dementia, these two categories were combined as outcome of dementia in subsequent analyses (Table 3).

Table 4 shows the basic- and multiadjusted ORs and 95% CIs of dementia, Alzheimer’s disease, and vascular dementia in association with diabetes derived from the GEE models. Diabetes was significantly related to increased risk of dementia, Alzheimer’s disease, and vascular dementia. The risk tended to be higher for vascular dementia than for Alzheimer’s disease. We also examined the effect of mid-life and late-life diabetes on dementia risk. Compared with patients with late-life diabetes, patients with mid-life diabetes appeared to be at a higher risk for dementia. The effect of mid-life diabetes on dementia risk remained statistically significant even after additional adjustment for diabetes duration (OR 2.07 [95% CI 1.12–3.68]).

All participants included 4,274 twin pairs and 5,117 single twins. Of 4,274 twin pairs, 4,071 were pairs in which both were nondemented and 47 were pairs in which both were demented, leaving 210 pairs discordant for dementia status. In the cotwin matched case-control analyses including both monozygotic and dizygotic pairs, the association between mid-life diabetes and dementia risk remained significant after adjustment for sex, education, stroke, heart disease, hypertension, and BMI at age 65 years, but the association with late-life diabetes largely attenuated and no longer statistically significant (0.68 [0.30–1.53]) (Table 5). The attenuation of the regressing coefficients between unpaired and paired analyses in twins suggests that factors that are common to twins in a pair contribute to the observed association in whole cohort. The ORs from GEE models based on all participants and those from conditional logistic models based on dementia-discordant pairs for the association of dementia with late-life diabetes were statistically significantly different (1.76 [1.08–2.88]; P = 0.02), but no difference was detected for the mid-life diabetes–dementia association (1.04 [0.55–1.99]; P = 0.89). The comparison of the results from the whole cohort and matched pairs indicated that the influences of genetic or family environmental factors on the association between mid-life diabetes and dementia might be small, but they play a role in the late-life diabetes–dementia association.

Among 13,693 participants, 2,633 died between the screening phase and 2004. In the GEE model, type 2 diabetes was related to an elevated risk of death with a multiadjusted OR of 2.15 (95% CI 1.87–2.47). We repeated the analysis using mean age of diabetes onset for 71 diabetic patients with missing age at diabetes onset, which produced the results that were much the same as those from the initial analysis. Further, combination of subjects with questionable dementia and nondemented subjects as control subjects did not alter the initial results. Finally, the analyses were repeated in 8,534 participants with mid-life BMI available, for which information on weight and height during the age of 40–65 years was taken from the Swedish

### Table 4

| Diabetes status | Subjects (n) | All dementia | Alzheimer’s disease | Vascular dementia |
|-----------------|-------------|--------------|---------------------|------------------|
| No              | 12,296      | 498; 1.00 (reference); 1.00 (reference) | 236; 1.00 (reference); 1.00 (reference) | 74; 1.00 (reference); 1.00 (reference) |
| Yes             | 1,396       | 139; 2.45 (1.97–3.03)*; 1.89 (1.51–2.38)† | 56; 2.03 (1.47–2.80)*; 1.69 (1.16–2.36)† | 31; 3.60 (2.33–5.57)*; 2.17 (1.36–3.47)† |
| Age of diabetes onset |         |              |                     |                  |
| <65 years       | 643         | 48; 2.95 (2.14–4.08)*; 2.76 (1.97–3.87)† | 16; 2.32 (1.37–3.94)*; 2.25 (1.29–3.92)† | 12; 4.94 (2.61–9.35)*; 3.94 (1.90–8.15)† |
| ≥65 years       | 753         | 91; 2.12 (1.64–2.75)*; 1.63 (1.23–2.16)† | 40; 1.88 (1.29–2.74)*; 1.56 (1.05–2.32)† | 19; 2.90 (1.70–4.94)*; 1.62 (0.92–2.80)† |

Data are n; OR (95% CI) or OR (95% CI). *Adjusted for age, sex, and education. †Adjusted for age, sex, education, stroke, heart disease, hypertension, and BMI.
neuroimaging studies have recently demonstrated that people with type 2 diabetes had moderately elevated risk for lacunes, hippocampal atrophy, and deep white matter lesions, which support the notion that the increased risk of cognitive decline and dementia in people with diabetes is probably due to dual pathological processes involving both cerebrovascular damage and neurodegenerative changes (35). In addition to microvascular and macrovascular disease, there are other pathophysiological mechanisms through which diabetes could increase the risk of dementia, including glycemia, insulin resistance, oxidative stress, advanced glycation end products, and inflammatory cytokines (20,36). Hyperinsulinemia is suggested to explain the increased risk of Alzheimer’s disease in diabetic patients, as the effect of high levels of insulin on dementia risk is independent of diabetes and blood glucose (37). These pathways may act separately or interactively, but which of these mechanisms are clinically relevant is unclear. In addition, the different mechanisms may interact during the long prodromal phases of both diabetes and dementia (38).

In cotwin control analyses, the risk effect of mid-life diabetes on dementia remained significant, but the association between late-life diabetes and dementia risk was largely diminished. Thus, the association between late-life diabetes and dementia may be attributed to genetic and early environmental factors (such as maternal nutrition status and childhood socioeconomic situation), although similar exposures at mid-life and late life could also have occurred. These findings suggest that the association observed in the unmatched case-control analysis between late-life diabetes and dementia is more likely to be endogenous. Our findings support recent evidence that the molecular defects associated with the development of diabetes also contribute to an increased risk of all types of dementia (39). Genome-wide association studies have shown that the insulin-degrading enzyme (IDE) gene links to both late-onset Alzheimer’s disease and type 2 diabetes (40). IDE has been demonstrated to degrade insulin and β-amyloid and to inhibit islet amyloid polypeptide (a protein coexpressed and secreted with insulin by β-cells) oligomer formation and cytotoxicity (41). There may be shared predisposition for developing islet amyloid in patients with diabetes and brain amyloid in those with Alzheimer’s disease. A population-based clinicopathological study (42) has shown the possible link between neurodegenerative processes that lead to loss of cortical brain cells in Alzheimer’s disease and the loss of β-cells in type 2 diabetes. Furthermore, there is now abundant evidence that early-life growth and development has an effect on risk of disease in adult life (43). Several studies have observed the relationship between low birth weight and increased risk of diabetes (44). In addition, childhood low socioeconomic status may also contribute to the risk of both diabetes (19) and dementia (45). Thus, the link between diabetes and dementia is probably determined by the complex interplay of genetic and environmental exposures throughout the life course.

In contrast to late-life diabetes, mid-life diabetes was associated with an increased risk of dementia even when controlling for genetic and familial factors, suggesting that mid-life diabetes—dementia association might be exogenous and is more likely attributable to adulthood environ-
ments (e.g., occupation and lifestyle such as exercise, diet, smoking, and social activities as well as glycemic control in patients with diabetes) (21). Our results indicate that genetic and unmeasured early-life environmental factors are likely to play a role in the association of late-life diabetes with dementia but could not explain mid-life diabetes in association with dementia, which implicated the involvement of adulthood environments in the development of mid-life diabetes–dementia association and highlighted the need to maintain a healthy lifestyle during adulthood in order to reduce the risk of dementia late in life.

Obesity is related to inflammation and insulin resistance, and the lifespan-dependent relation of obesity with dementia has been reported (46). In our study, information on weight and height were based on self- or informant report, and BMI as a covariate in the analyses may lead to residual confounding. However, all our analyses showed that BMI did not substantially affect the diabetes-dementia association, suggesting that the confounding due to BMI on the diabetes-dementia association, if it exists, is likely to be minimal.

Some limitations of the study should be mentioned. First, the use of prevalent dementia cases may have introduced some confounding effect due to differential survival among case subjects. In this study, the mean age of diabetes onset was much younger than the mean age of dementia onset. The temporality of the given association is clear. In addition, diabetes is associated with an elevated mortality in our study as reported previously (47), which would probably lead to an underestimation of the strength of association between diabetes and dementia risk. Second, we identified patients with diabetes based on self- and informant-reported information and in inpatient medical history. Information on blood glucose concentration was not available. Because diabetes is commonly (~30%) undiagnosed in elderly people (48), in this study a substantial proportion of the subjects with diabetes might have been erroneously assigned to the nondiabetic group, which would also lead to an underestimation of the risk attributable to diabetes. Third, both sets of influences are anonymous; thus, we are unable to infer which genes might be involved or which environmental factors may be important. Fourth, information from informants was used for participants who could not provide information about history of diseases due to impaired cognition (7.0%). However, the bias of using reports from an informant has been previously found to be minimal (49). Finally, both diabetes and dementia (especially Alzheimer’s disease) are genetically influenced disorders with substantial concordance in twins (15,50). Thus, the matched pairs could be regarded as “overmatched,” as twin pairs are similar on many aspects, such as genetic susceptibility and lifestyle. Nevertheless, the comparison of the results from the cohort as a whole with the matched pairs provides important information about the potential role of genetic and familial influences in the associations from the cohort analyses. Furthermore, as the discordant pairs included both monozygotic and dizygotic twins, genetic effects were not perfectly controlled for.

In conclusion, our results show that diabetes increases the risk of Alzheimer’s disease and vascular dementia in the Swedish twins. The risk effect is stronger when diabetes occurs at mid-life than in late life. These findings add to the growing evidence of a link between diabetes, vascular damage, and neurodegenerative changes in the brain.

Genetic and early-life environmental factors might contribute to the association between late-life diabetes and dementia, but adulthood environments might be responsible for mid-life diabetes–dementia association. These findings suggest that diabetes-dementia association may develop across a lifespan. Further studies are required to reveal which early life and adulthood environmental factors as well as genes might be involved for the diabetes-dementia association.

ACKNOWLEDGMENTS

Research grants were received from the National Institute on Aging (R01-AG08724), the American Alzheimer’s Association (ZEN-02-3895 and IIRG-03-5963), the Swedish Research Council in Medicine, and the Swedish Brain Power.

This study was also supported, in part, by private funds from the Gamla Tjänarinnor, the Bertil Stohnes Foundation, and Lindhés Advokatbyrå AB (Sweden). No other potential conflicts of interest relevant to this article were reported.

We thank all members in the HARMONY Study Group for data collection and management.

REFERENCES

1. Leibson CL, Rocca WA, Hanson VA, Cha R, Kolmen E, O’Brien PC, Palumbo PJ. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 145:301–308, 1997
2. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM: Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 53:1937–1942, 1999
3. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R: Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154:635–641, 2001
4. Hassing LB, Johansson B, Nilsson SE, Berg S, Pedersen NL, Gatz M, McClearn G: Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer’s disease: a population-based study of the oldest old. Int Psychogeriatr 14:239–248, 2002
5. Peila R, Rodriguez BL, Launer LJ: Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 51:1256–1262, 2002
6. MacKnight C, Rockwood K, Awalt E, McDowell I: Diabetes mellitus and the risk of dementia, Alzheimer’s disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 14:77–83, 2002
7. Luchsinger JA, Tang MX, Shea S, Mayeux R: Hyperinsulinemia and risk of Alzheimer disease. Neurology 63:1187–1192, 2004
8. Schneider Beeri M, Goldbourt U, Silverman JM, Noy S, Schneider J, Ravona-Springer R, Seerdlick A, Davidson M: Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 63:1902–1907, 2004
9. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA: Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 61:661–666, 2004
10. Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L: Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 63:1181–1186, 2004
11. Borenstein AR, Wu Y, Mortimer JA, Schellenberg GD, McCormick WC, Bowen JD, McCurry S, Larson EB: Developmental and vascular risk factors for Alzheimer’s disease. Neurobiol Aging 26:325–334, 2005
12. Akomolafe A, Beiser A, Meigs JB, Au R, Green RC, Farrer LA, Wolf PA, Seshadri S: Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Arch Neurol 63:1551–1555, 2006
13. Xu W, Qiu C, Winblad B, Fratiglioni L: The effect of borderline diabetes on the risk of dementia and Alzheimer’s disease. Diabetes 56:211–216, 2007
14. Launer LJ: Diabetes and brain aging: epidemiologic evidence. Curr Diab Rep 5:59–63, 2005
15. O’Rahilly S, Barroso I, Wareham NJ: Genetic factors in type 2 diabetes: the end of the beginning? Science 307:370–373, 2005
16. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske A, Pedersen NL: Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiary 63:168–174, 2006
17. Iliadou A, Cnattingius S, Lichtenstein P: Low birthweight and type 2 diabetes mellitus among women: a population-based cohort study. Am J Epidemiol 154:635–641, 2001

76 DIABETES, VOL. 58, JANUARY 2009
diabetes: a study on 11 162 Swedish twins. Int J Epidemiol 33:948–953, 2004; discussion 953–944

18. Poulsen P, Vaag A: The intrauterine environment as reflected by birth size and twin and zygosity status influences insulin action and intracellular glucose metabolism in an age- or time-dependent manner. Diabetes 55:1819–1825, 2006

19. Langenberg C, Araneta MR, Bergstrom J, Marmot M, Barrett-Connor E: Diabetes and coronary heart disease in Filipino-American women: role of growth and life-course socioeconomic factors. Diabetes Care 30:535–541, 2007

20. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P: Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5:64–74, 2006

21. Whalley LJ, Dick FD, McNeill G: A life-course approach to the aetiology of late-onset dementia. Lancet Neurol 5:87–96, 2006

22. Lichtenstein P, De Faire U, Fodorus B, Svartengren M, Svedberg P, Pedersen NL: The Swedish Twin Registry: a unique resource for clinical, epidemiological and genetic studies. J Intern Med 252:184–205, 2002

23. Gatz M, Fratiglioni L, Johansson B, Berg S, Mortimer JA, Reynolds C, Fiske A, Pedersen NL: Complete ascertainment of dementia in the Swedish Twin Registry: the HARMONY study. Neurobiol Aging 26:439–447, 2005

24. Gatz M, Reynolds C, Nikoile J, Lowe B, Karel M, Pedersen N: An empirical test of telephone screening to identify potential dementia cases. Int Psychogeriatr 7:429–438, 1995

25. Gatz M, Reynolds CA, John R, Johansson B, Mortimer JA, Pedersen NL: Telephone screening to identify potential dementia cases in a population-based sample of older adults. Int Psychogeriatr 14:273–289, 2002

26. Blessed G, Tomlinson BE, Roth M: The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 114:797–811, 1968

27. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC, American Psychiatric Association, 1994

28. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944, 1984

29. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orloogozo JM, Brun A, Hofman A, et al.: Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AREN International Workshop. Neurology 43:250–260, 1993

30. Fiske A, Gatz M, Aadnoy B, Pedersen NL: Assessing age of dementia onset: validity of informant reports. Alzheimer Dis Assoc Disord 19:128–134, 2005

31. Klokpenborg RP, van den Berg E, Kappelle LJ, Biessels GJ: Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur J Pharmacol 585:97–108, 2008

32. Gatz M, Svedberg P, Pedersen NL, Mortimer JA, Berg S, Johansson B: Education and the risk of Alzheimer’s disease: findings from the study of dementia in Swedish twins. J Gerontol B Psychol Sci Soc Sci 56:P292–P300, 2001

33. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R: Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 65:545–551, 2005

34. Bruce DG, Davis WA, Casey GP, Starkstein SE, Clarinette RM, Foster JK, Almeida OP, Davis TM: Predictors of cognitive impairment and dementia in older people with diabetes. Diabetologia 51:241–248, 2008

35. van Herten B, de Leeuw FE, Weinstein HC, Scheltens P, Biessels GJ: Brain imaging in patients with diabetes: a systematic review. Diabetes Care 29:2539–2548, 2006

36. Whitmer RA: Type 2 diabetes and risk of cognitive impairment and dementia. Curr Neurol Neurosci Rep 7:373–380, 2007

37. Pella R, Rodriguez BL, White LR, Launer LJ: Fasting insulin and incident dementia in an elderly population of Japanese-American men. Neurology 63:228–233, 2004

38. Stewart R, Liolaia D: Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med 16:110–112, 1999

39. Cole AR, Aster A, Green C, Sutherland C: Molecular connections between dementia and diabetes. Neurosci Biobehav Rev 31:1046–1063, 2007

40. Qiu WQ, Folstein MF: Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer’s disease: review and hypothesis. Neurobiol Aging 27:190–198, 2006

41. Haataja L, Gurlo T, Huang CJ, Butler PC: Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr Rev 29:303–316, 2008

42. Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC: Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53:474–481, 2004

43. de Bo HA, Harding JE: The developmental origins of adult disease (Barker) hypothesis. Aust NZ J Obstet Gynaecol 46:4–14, 2006

44. Jones RH, Oram SE: Intra-uterine origins of type 2 diabetes. Arch Physiol Biochem 113:25–29, 2007

45. Borenstein AR, Copenhaver CI, Mortimer JA: Early-life risk factors for Alzheimer disease. Alzheimer Dis Assoc Disord 20:63–72, 2006

46. Whitmer RA: The epidemiology of adiposity and dementia. J Alzheimers Res 4:117–122, 2007

47. Fox CS, Coody S, Sorlie PD, Levy D, Meigs JB, D’Agostino RB Sr, Wilson PW, Savage PJ: Trends in cardiovascular complications of diabetes. JAMA 292:2405–2409, 2004

48. Gregg EW, Cadwell BL, Cheng YJ, Cowie CC, Williams DE, Geiss LS, Engelgau MM, Vinicor F: Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the U.S. Diabetes Care 27:2806–2812, 2004

49. Denisse S, Green RC, Mucci L, Tzivkas S, Martelli K, Bang K, Coons L, Bourque S, Buchillon D, Johnson K, Smith T, Sharrow N, Laurencslager N, Friedland R, Gapples LA, Farrer LA: Reliability of information collected by proxy in family studies of Alzheimer’s disease. Neuroepidemiology 20:105–111, 2001

50. Pedersen NL, Gatz M, Berg S, Johansson B: How heritable is Alzheimer’s disease late in life? Findings from Swedish twins. Ann Neurol 55:180–185, 2004